Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canada warns against sex enhancement drug

This article was originally published in The Tan Sheet

Executive Summary

Canadian consumers are warned against using Adam, an unauthorized product for erectile dysfunction, as it may pose serious health risks, especially for patients with pre-existing medical conditions, Health Canada says in a statement March 10. The product contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil, which is used under the supervision of a physician, the agency says. Heart disease patients who use sildenafil can experience cardiovascular side effects including heart attack and stroke, Health Canada notes. Distributor Natural Health Solutions conducted a voluntary recall of Adam, which was sold in retail outlets throughout Canada and on the Internet. Due to the proliferation of erectile dysfunction supplements containing prescription ingredients in the U.S., the United Natural Products Alliance is urging the supplement industry to take steps to keep these products off the market (1"The Tan Sheet" Jan. 28, 2008, p. 11)...

You may also be interested in...

FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA

The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts